sb 203580 has been researched along with cefpodoxime in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (cefpodoxime) | Trials (cefpodoxime) | Recent Studies (post-2010) (cefpodoxime) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 11 | 0 | 8 |
| Protein | Taxonomy | sb 203580 (IC50) | cefpodoxime (IC50) |
|---|---|---|---|
| Angiopoietin-1 receptor | Homo sapiens (human) | 0.25 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, JL; Feng, Y; Hansbury, M; Johnson, N; Semones, M; Winkler, J | 1 |
1 other study(ies) available for sb 203580 and cefpodoxime
| Article | Year |
|---|---|
Pyridinylimidazole inhibitors of Tie2 kinase.
Topics: Animals; Cell Line, Tumor; Drug Design; Enzyme Inhibitors; Humans; Imidazoles; Inhibitory Concentration 50; Mice; Models, Chemical; Models, Molecular; Neoplasm Transplantation; p38 Mitogen-Activated Protein Kinases; Plasmacytoma; Pyridines; Receptor, TIE-2 | 2007 |